TrialJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2021

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.

Carsten Schwarz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.